| Advanced Digital Technology Solutions are Getting Attention by Reducing New Drug Development Time and Costs, and Maximizing Accuracy and Efficiency
| Capabilities to Enhance Overall New Drug Development Processes, from Candidate Substance Exploration to Clinical Data Management and Analysis
As various industries are intensifying their IT transition movements, the new drug development market is also experiencing a digital revolution. According to industry sources, the traditional new drug development process typically requires an average of 10 years and costs over 12 trillion won. The early candidate substance stage involves analyzing vast amounts of data, and even after transitioning to the clinical trial phase, reviewing each trial's results consumes significant time.
However, advanced technologies that minimize these complex processes and opportunity costs while maximizing accuracy and efficiency are enhancing the drug development capabilities of the pharmaceutical and biotech industries. Consequently, the competitiveness of domestic pharmaceutical companies in new drug development is steadily increasing.
■ JNPMEDI's 'Maven Clinical Cloud': Enabling Low-Cost, High-Efficiency New Drug Development
Medical data platform company JNPMEDI has developed the digital-based clinical operations and data management solution 'Maven Clinical Cloud,' driving innovation in the clinical trial industry.
Maven Clinical Cloud, provided as a Software-as-a-Service (SaaS), enables systematic management of extensive data across the entire clinical trial process. Designed with an open architecture, it can flexibly integrate with various digital healthcare devices, including AI medical devices and wearables. Key services of Maven Clinical Cloud include the decentralized clinical trial (DCT) solution 'Maven DCT Suite' and the clinical trial document management solution 'Maven Docs.' These services are available at more reasonable costs through a pay-as-you-go pricing model tailored to the clinical trial's scale and purpose.
To ensure stable operation throughout the clinical trial process, JNPMEDI is actively collaborating with various industry stakeholders. Based on this foundation, the company is providing solutions across multiple medical fields, including pharmaceuticals, biotechnology, digital therapeutics, and digital medical devices, leading the advancement of clinical trials.
As the clinical methods are gradually achieving digital transformation, which is expected to become the new standard post-pandemic, JNPMEDI is gaining attention as a leading and technology-driven promising company. Particularly, inquiries from pharmaceutical companies preparing for new drug development are increasing.
Moreover, JNPMEDI has joined the global standard 'Decentralized Trials & Research Alliance (DTRA)' and is focusing on service enhancement based on advanced global cases.
| Advanced Digital Technology Solutions are Getting Attention by Reducing New Drug Development Time and Costs, and Maximizing Accuracy and Efficiency
| Capabilities to Enhance Overall New Drug Development Processes, from Candidate Substance Exploration to Clinical Data Management and Analysis
As various industries are intensifying their IT transition movements, the new drug development market is also experiencing a digital revolution. According to industry sources, the traditional new drug development process typically requires an average of 10 years and costs over 12 trillion won. The early candidate substance stage involves analyzing vast amounts of data, and even after transitioning to the clinical trial phase, reviewing each trial's results consumes significant time.
However, advanced technologies that minimize these complex processes and opportunity costs while maximizing accuracy and efficiency are enhancing the drug development capabilities of the pharmaceutical and biotech industries. Consequently, the competitiveness of domestic pharmaceutical companies in new drug development is steadily increasing.
■ JNPMEDI's 'Maven Clinical Cloud': Enabling Low-Cost, High-Efficiency New Drug Development
Medical data platform company JNPMEDI has developed the digital-based clinical operations and data management solution 'Maven Clinical Cloud,' driving innovation in the clinical trial industry.
Maven Clinical Cloud, provided as a Software-as-a-Service (SaaS), enables systematic management of extensive data across the entire clinical trial process. Designed with an open architecture, it can flexibly integrate with various digital healthcare devices, including AI medical devices and wearables. Key services of Maven Clinical Cloud include the decentralized clinical trial (DCT) solution 'Maven DCT Suite' and the clinical trial document management solution 'Maven Docs.' These services are available at more reasonable costs through a pay-as-you-go pricing model tailored to the clinical trial's scale and purpose.
To ensure stable operation throughout the clinical trial process, JNPMEDI is actively collaborating with various industry stakeholders. Based on this foundation, the company is providing solutions across multiple medical fields, including pharmaceuticals, biotechnology, digital therapeutics, and digital medical devices, leading the advancement of clinical trials.
As the clinical methods are gradually achieving digital transformation, which is expected to become the new standard post-pandemic, JNPMEDI is gaining attention as a leading and technology-driven promising company. Particularly, inquiries from pharmaceutical companies preparing for new drug development are increasing.
Moreover, JNPMEDI has joined the global standard 'Decentralized Trials & Research Alliance (DTRA)' and is focusing on service enhancement based on advanced global cases.